Table 1. Patient characteristics.
| Characteristics | Gefitinib (n=144) | Erlotinib (n=26) |
|---|---|---|
| Age (years), median (range) | 65.0 [32–81] | 61.5 [27–68] |
| Sex, n (%) | ||
| Male | 58 (40.3) | 15 (57.7) |
| Female | 86 (59.7) | 11 (42.3) |
| ECOG PS, n (%) | ||
| 0–1 | 131 (91.0) | 23 (88.5) |
| 2–4 | 8 (5.6) | 3 (11.5) |
| Unknown | 5 (3.4) | 0 |
| Smoking history, n (%) | ||
| Never | 88 (61.1) | 14 (53.8) |
| Ever | 52 (36.1) | 11 (42.3) |
| Unknown | 4 (2.8) | 1 (3.8) |
| Clinical stage, n (%) | ||
| IIIB | 2 (1.4) | 0 |
| IV | 81 (56.3) | 18 (69.2) |
| Recurrence | 61 (42.4) | 8 (30.8) |
| Histology, n (%) | ||
| Adenocarcinoma | 144 [100] | 26 [100] |
| EGFR mutation, n (%) | ||
| Ex 19 del | 82 (56.9) | 16 (61.5) |
| Ex 21 L858R | 62 (43.1) | 10 (38.5) |
| CNS metastases before EGFR-TKI, n (%) | ||
| Positive | 38 (26.4) | 5 (19.2) |
| Negative | 106 (73.6) | 21 (80.8) |
| Interval of brain imaging test (months), median (range) | 3.0 [1–8] | 3.0 [1–6] |
ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; CNS, central nervous system; TKI, tyrosine kinase inhibitor; Ex, exon; Del, deletion; RT, radiation therapy.